March is here, and as we observe Kidney Month, it’s crucial to raise awareness about how lupus can severely impact the ...

In a new study, researchers investigated microRNA-203 as a potential biomarker for lupus nephritis (LN) and found that ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

WEDNESDAY, Feb. 26, 2025 (HealthDay News) -- For patients with active lupus nephritis, obinutuzumab, a humanized type II anti ...

Nat Clin Pract Nephrol. 2007;3(6):296-297. How did this transfer of 'ownership' of lupus nephritis to rheumatologists happen? There are two possible reasons. Either rheumatologists hijacked lupus ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...

1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over intravenous cyclophosphamide for the induction of remission in patients with lupus nephritis.

The following is a summary of “Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis,” published in the February 2025 ...

Aurinia can still see growth in product revenues from Lupkynis and has a chance to show that AUR200 has some value in 2025.

1 More than 1.5 million people develop one of the most dangerous manifestations of SLE: lupus nephritis (LN), characterized by immune system induced inflammation of the kidneys. Within 10 years ...